Understanding donor-specific antibodies after incompatible stem cell transplants
Kinectics of Donor-specific Anti-HLA Antibody After HLA-incompatible Allogeneic Haematopoietic Stem Cell Transplantation
This study looks at how common certain antibodies are in patients who received stem cell transplants from donors with different tissue types to see what might help prevent complications like graft rejection.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 15 Years to 60 Years |
| Sex | All |
| Sponsor | Peking University People's Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT06395220 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the presence and factors influencing donor-specific anti-HLA antibodies (DSA) in patients who have undergone HLA-incompatible allogeneic hematopoietic stem cell transplantation. It aims to clarify the rate of DSA positivity post-transplantation and identify risk factors associated with it. By utilizing a prospective, registry-based clinical cohort, the study seeks to provide insights that could help in preventing graft rejection and primary graft failure (PGF) in these patients.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 15 to 60 years with a clinical diagnosis of hematological disorders who are undergoing HLA-incompatible allogeneic stem cell transplantation.
Not a fit: Patients who are unable to provide informed consent due to psychiatric or physical illness will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved strategies for preventing graft rejection and enhancing transplant outcomes for patients with hematological malignancies.
How similar studies have performed: While many studies have focused on DSA levels before transplantation, this study's focus on post-transplant DSA positivity is relatively novel and less explored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Clinical diagnosis haematological disorders undergoing HLA-incompatible allogeneic haematopoietic stem cell transplantation Between 15 and 60 years-old Must sign the informed consent Exclusion Criteria: Withdraw of the signed informed consent for any reason Lack of ability to provide consent due to psychiatric or physical illness
Where this trial is running
Beijing
- People's Hospital of Peking University — Beijing, China (Recruiting)
Study contacts
- Study coordinator: Prof. Ying-Jun Chang Chang
- Email: rmcyj@bjmu.edu.cn
- Phone: 8610-88325949
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.